CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
CTMX filed a patent for "activatable cytokine constructs and combination methods" on Thu, January 25, 2024. The patent was officially published on Thu, January 23, 2025.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
